Nov 11, 2023 11:30 am EST Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
Nov 07, 2023 4:05 pm EST Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 02, 2023 10:00 am EDT Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting
Oct 31, 2023 4:05 pm EDT Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
Oct 13, 2023 4:10 pm EDT Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023
Sep 14, 2023 4:05 pm EDT Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas
Sep 11, 2023 4:05 pm EDT Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023
Sep 10, 2023 7:47 am EDT Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension
Sep 10, 2023 7:45 am EDT Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions